Bedtime Device Restriction and Desmopressin in PMNE.
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-14
SponsorAl-Azhar University
About this trial
This randomized controlled trial will evaluate whether restricting bedtime digital-device use improves the response to desmopressin in children with primary monosymptomatic nocturnal enuresis. Participants will receive desmopressin for 8 weeks and will be assigned to either bedtime device restriction or usual screen habits.
Eligibility criteria
Qualifiers
Age 6-14 years.
Diagnosis of PMNE (≥2 wet nights/week for ≥6 months, no daytime symptoms, no prior sustained dryness >6 months).
Willingness to take oral desmopressin nightly for 8 weeks.
Parent/guardian able to monitor and report screen time and wet nights.
Disqualifiers
Secondary enuresis or non-monosymptomatic enuresis (daytime incontinence, urgency, frequency).
Known organic causes (e.g., diabetes mellitus, urinary tract anomalies, neurological disorders).
Current use of other enuresis treatments (alarms, anticholinergics, imipramine) within 4 weeks prior to enrollment.
Severe sleep disorders (e.g., obstructive sleep apnea) or psychiatric conditions affecting compliance.
Trial design
Treatments tested in this trial
- Desmopressin
- Bedtime digital-device restriction
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov